Implementation Facilitation Period vs Pre-Implementation Period: Use of Sedative Prescriptions During Implementation Among Patients With OUD
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.316 | 0.303 | 0.329 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.292 | 0.276 | 0.309 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.0233 | 0.0024 | 0.044 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.08 | 1.01 | 1.16 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.12 | 1.01 | 1.23 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on Implementation Facilitation Period than on Pre-Implementation Period | 42.9 | 22.8 | 417 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Implementation Facilitation Period | Implementation Facilitation: The foundation of CONDUIT's implementation activities are the structured interactions between external facilitation teams and internal facilitation teams. A core set of internal facilitation activities will be used across all facilitation teams, and external facilitation teams will use additional activities based on the needs of their sites or clinical settings.~The start date of the implementation facilitation period for each site was reported by the study PI. | 1,538 | 4,872 | OG000 | ClinicalTrials.gov |
| Group 2 | Pre-Implementation Period | Pre-implementation period defined as the 12 months prior to the implementation start date for each site. | 888 | 3,037 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Use of Sedative Prescriptions During Implementation Among Patients With OUD | ClinicalTrials.gov |
| Description | This is the count/percentage of people exposed to any sedative prescriptions as determined by patients' electronic health records. | ClinicalTrials.gov |
| Time frame | The implementation period varies by site and will likely range from 6 months to 18 months. This outcome is compared to 12-month the pre-implementation period. | ClinicalTrials.gov |
| Population | Patients were counted as having a prescription for benzodiazepines if they were dispensed at least 1 prescription of benzodiazepines at any time during the phase. Patients were included in the numerator if they had a qualifying prescription during the phase. They were included in the denominator for each phase in which they had a qualifying opioid use disorder diagnosis. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Consortium to Disseminate and Understand Implementation of Opioid Use Disorder Treatment | ClinicalTrials.gov |
| NCT number | NCT04178551 | ClinicalTrials.gov |
| Phases | NA | ClinicalTrials.gov |
| Conditions | Opioid Medication Assisted Treatment | ClinicalTrials.gov |
| Interventions | Implementation Facilitation | ClinicalTrials.gov |
| Lead sponsor | VA Office of Research and Development | ClinicalTrials.gov |
| Results first posted | 2025-11-10 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT04178551?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.